GSAR Journal of Agriculture and Veterinary Sciences
ISSN: 3048-9075 (Online)
Abbreviated key title: Glob.J. Agri.Vet.Sci.
Frequency: Monthly
Published By GSAR Publishers
Journal Homepage Link- https://gsarpublishers.com/journal-gjavs-home/

CRISPR and Gene Editing: Revolutionary Advances and Future Prospects in Medicine and Agriculture

By

Muhammad Ahmad Saeed[1], Hifsa Khalid[2], Muhammad Ahmad Sardar[3], Muhammad Shahzad Shafiq[4], Sidra Munir[5], Shaheen Sadique[6], Umber Rauf[7], Muhammad Abbas[8], Hafiz Munsif Alam[9], Sehar Rafique[10*]

[1]Department of Botany, Government College University Faisalabad, Punjab 38000, Pakistan
[2]Department of Botany, Government College University Faisalabad, Punjab 38000, Pakistan
[3]Department of Biotechnology, Sarhad University, Peshawar, KPK, Pakistan
[4]Department of Pathology, Faculty of Veterinary Science, University of Agriculture Faisalabad, Punjab, Pakistan
[5]IMBB, University of Lahore, Punjab, Pakistan
[6]Department of Chemistry, University of Agriculture Faisalabad, Punjab, Pakistan
[7]Veterinary Research Institute, Zarrar Shaheed Road, Lahore Cantt, Punjab, Pakistan
[8]Department of Zoology, Qurtuba University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan
[9]Department of Microbiology, Quaid-e-Azam University, Islamabad, Punjab, Pakistan
[10]Department of Zoology, Division of Science and Technology, University of Education, Lahore, Punjab 54470, Pakistan.

Article History

Received: 15/032025
Accepted: 23/03/2025
Published: 25/03/2025

Vol – 2 Issue – 3

PP: -50-70

DOI:10.5281/zenodo.15173339

Abstract

The CRISPR-Cas9 genome-editing breakthrough revolutionises biotechnology by providing unmatched precision, efficiency, and versatility. Initially a bacterial immune response, CRISPR has evolved into a powerful tool in medicine, agriculture, and synthetic biology. By employing a programmable single-guide RNA (sgRNA) that directs the Cas9 endonuclease, this system allows for targeted genetic modifications with remarkable accuracy. In the medical field, CRISPR spearheads advances in gene therapy, cancer immunotherapy, and the treatment of genetic illnesses such as sickle cell anemia and cystic fibrosis. Its capability to edit DNA with precision has opened new avenues for personalised medicine and regenerative treatments. CRISPR is creating climate-resilient crops that boast higher yields, improved disease resistance, and enhanced nutritional value in agriculture, fundamentally changing food security. Additionally, it is influencing future livestock breeding by fostering disease resistance and lessening reliance on antibiotics. Beyond healthcare and agriculture, CRISPR is also making strides in synthetic biology, supporting microbial engineering for biofuel production, industrial enzyme development, and environmental bioremediation. Nevertheless, despite its immense potential, CRISPR encounters significant challenges such as off-target mutations, ethical dilemmas, and regulatory scrutiny. Progress in the development of high-fidelity Cas9 variants, base and prime editing, and AI-enhanced CRISPR tools, continues to refine this technology, improving its precision and safety. As CRISPR transforms genome engineering, this review delves into its mechanisms, revolutionary applications, ethical considerations, and prospective effects on biotechnology and medicine.

Introduction

The advent of CRISPR-Cas9 technology has revolutionised the field of genome editing, offering an unprecedented level of precision, efficiency, and versatility. Originally discovered as a natural immune defense mechanism in bacteria, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has evolved into a powerful gene-editing tool with

*Corresponding Author: **Sehar Rafique**

applications spanning medicine, agriculture, and biotechnology. Unlike earlier genome-editing techniques such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs), CRISPR-Cas9 provides a more straightforward, more cost-effective, and particular means of modifying genetic material (Aljabali et al., 2024; Doudna & Charpentier, 2012; Jinek et al., 2012).

The fundamental mechanism of CRISPR-Cas9 involves a Cas9 endonuclease guided by a synthetic single-guide RNA (sgRNA) to target specific genomic sequences. Once bound, Cas9 introduces a double-strand break (DSB) at the designated site, triggering cellular repair mechanisms such as Non-Homologous End Joining (NHEJ) **or** Homology-Directed Repair (HDR), which can be leveraged to introduce targeted genetic modifications (Guo et al., 2023; Xu & Li, 2020; Makarova et al., 2015; Barrangou & Horvath, 2017). The system's adaptability and high efficiency have positioned it as a groundbreaking tool in gene therapy, precision medicine, and crop improvement (Liu et al., 2021; Hsu et al., 2014; Ledford, 2019).

The discovery of CRISPR dates back to the early 1980s when scientists identified repetitive DNA sequences in bacterial genomes, but it was not until 2007 that their function as an adaptive immune system was confirmed (Makarova & Koonin, 2015; Barrangou et al., 2007; Ishino et al., 1987). Further advancements in 2012 by Jennifer Doudna and Emmanuelle Charpentier demonstrated its potential for programmable genome editing in eukaryotic cells, marking the beginning of a new era in biotechnology (Hossain, 2021; Jinek et al., 2012; Mojica & Díez-Villaseñor, 2013). The simplicity and efficiency of CRISPR-Cas9 technology have allowed it to surpass other genome-editing methods and become the dominant approach in genetic research and applications (Cong et al., 2013; Jinek et al., 2012).



Graph: ***Impact of CRISPR-Cas9 Technology Across Various Fields***

CRISPR-Cas9 has transformed multiple scientific fields by providing an efficient, cost-effective, and particular tool for modifying DNA sequences. In medicine, it is being explored for treating genetic disorders such as sickle cell anemia, cystic fibrosis, Huntington's disease, and Duchenne muscular dystrophy. CRISPR-based therapies are being developed to combat cancers by modifying immune cells for CAR-T therapy, and it has also shown potential in tackling viral infections such as HIV and SARS-CoV-2 (Cong et al., 2013; Wu et al., 2023; Komor et al., 2016). The ability to precisely correct mutations in genetic diseases represents a paradigm shift in personalised medicine and therapeutic interventions (Zhang et al., 2022; Kim et al., 2021).

In agriculture, CRISPR technology is driving advances in crop genetic engineering by improving resistance to pests, diseases, and environmental stressors while enhancing yield and nutritional quality (Zhu, 2022; Gao et al., 2020; Nekrasov et al., 2017). Crops such as rice, wheat, and tomatoes have been successfully modified using CRISPR to improve productivity and nutritional value. This technology also facilitates the precise removal of allergens and toxins from food sources, making agricultural products safer and more beneficial for consumption (Shan et al., 2013; Svitashev et al., 2015). Livestock breeding is also being revolutionised with CRISPR by enabling the selection of desirable genetic traits and reducing susceptibility to diseases (Crispo et al., 2015; Tan et al., 2022).

CRISPR also holds promise in synthetic biology, where it is being used to engineer microbial strains for biofuel production, industrial enzyme synthesis, and environmental bioremediation (Bhattacharjee et al., 2022; Komor et al., 2016; Dominguez et al., 2022). Microorganisms modified with CRISPR can efficiently degrade pollutants, convert waste into biofuels, and produce valuable biochemical compounds, paving the way for sustainable industrial biotechnology (Choi et al., 2021; Jiang et al., 2020).

Despite its revolutionary potential, CRISPR-Cas9 is not without limitations. Off-target effects remain a significant concern, where unintended genetic modifications can lead to unpredictable consequences (Sahel et al., 2023; Kleinstiver et al., 2016; Ledford, 2019; Pattanayak et al., 2013). Efforts are ongoing to improve target specificity through engineered Cas9 variants and optimised guide RNA design (Bolukbasi et al., 2015; Slaymaker et al., 2016). Ethical concerns surrounding germline editing, particularly in human embryos, continue to spark global debates regarding the responsible use of CRISPR in reproductive medicine (Ishii, 2017; Lanphier et al., 2015). Regulatory challenges vary across different countries, with some governments imposing strict controls on CRISPR applications while others encourage its development within ethical boundaries (Doudna, 2020; Ledford, 2019).

This review aims to comprehensively analyse CRISPR-Cas9, examining its mechanisms, advancements, applications, ethical considerations, and future prospects. By addressing both the potentials and challenges associated with CRISPR, this article contributes to an informed discussion about the future trajectory of genome editing technology and its implications for science, medicine, and industry (Hsu et al., 2014; Kleinstiver et al., 2016).

Table: ***Comparison of CRISPR-Cas9 with Other Genome-Editing Technologies***

Feature	CRISPR-Cas9	Zinc Finger Nucleases (ZFNs)	Transcription Activator-Like Effector Nucleases

*Corresponding Author: **Sehar Rafique**

			(TALENs)
Discovery	Bacterial immune defense (2007)	Early 1990s	2010
Key Components	Cas9 enzyme + guide RNA (sgRNA)	Protein-DNA interactions	Protein-DNA interactions
Targeting Mechanism	RNA-guided	Protein-guided	Protein-guided
Editing Efficiency	High	Moderate	Moderate
Cost-effectiveness	Low-cost	High-cost	High-cost
Ease of Design	Simple	Complex	Complex
Off-target Effects	Moderate (improving with new variants)	Low	Low
Applications	Medicine, agriculture, synthetic biology	Mainly research, gene therapy	Research, gene therapy

2. CRISPR-Cas System and Mechanism

a) **Mechanism of CRISPR-Cas9 Genome Editing**

The CRISPR-Cas9 system operates through a sophisticated three-step mechanism: recognition, cleavage, and repair. The process begins when a specifically designed single-guide RNA (sgRNA) binds to the target DNA sequence via complementary base pairing. This interaction occurs at a protospacer adjacent motif (PAM) site, a short conserved DNA sequence that acts as a necessary recognition element for Cas9 to initiate cleavage (Jinek et al., 2012; Sternberg et al., 2014). Once the PAM site is identified, the Cas9 endonuclease is activated and introduces a double-strand break (DSB) precisely three nucleotides upstream from the PAM sequence (Gasiunas et al., 2012; Doudna & Charpentier, 2014). Cas9 consists of two key domains—HNH and RuvC—which function as molecular scissors. The HNH domain cleaves the complementary DNA strand, while the RuvC domain cuts the non-complementary strand. This results in the formation of blunt-ended DSBs, triggering the host cell's natural DNA repair mechanisms (Ran et al., 2013; Wright et al., 2016).

Table: ***CRISPR-Cas9 System and Its Genome Editing Mechanism***

Category	Description	Key Components	Examples and References
Mechanism of CRISPR-Cas9 Genome Editing	A three-step process involving **recognition, cleavage, and repair**. The sgRNA binds to the target DNA at a PAM site, guiding the Cas9 enzyme to introduce a **double-strand break (DSB)**.	- **sgRNA (single-guide RNA)**: Guides Cas9 to the target sequence. - **Cas9 Endonuclease**: Introduces a site-specific DSB. - **PAM (Protospacer Adjacent Motif)**: A necessary recognition sequence (e.g., NGG in Cas9).	Jinek et al., 2012; Sternberg et al., 2014
Cas9 Structure and Function	Cas9 consists of two active nuclease domains: **HNH** and **RuvC**, responsible for cutting the complementary and non-complementary DNA strands, respectively.	- **HNH domain**: Cleaves the target strand. - **RuvC domain**: Cleaves the non-target strand. - **Nickase Cas9 (Cas9n)**: Introduces single-strand cuts to reduce off-target effects.	Gasiunas et al., 2012; Doudna & Charpentier, 2014
Double-Stranded Break (DSB) Repair Pathways	The cell repairs DSBs using one of two mechanisms: **Non-Homologous End Joining (NHEJ)** or **Homology-Directed Repair (HDR)**.	- **NHEJ**: An error-prone mechanism leading to insertions/deletions (indels), useful for gene knockouts. - **HDR**: A precise repair mechanism using a homologous template, suitable for gene insertions and corrections.	Maruyama et al., 2015; Richardson et al., 2016
CRISPR-Based DNA	Strategies to enhance HDR	- **Small molecules (RS-1, SCR7)**	Pinder et al., 2015; Bothmer

*Corresponding Author: **Sehar Rafique**

Repair Modulation	efficiency and bias the repair process towards precise modifications.	enhance HDR efficiency. - **Cas9 fusion proteins** (Cas9-CTP, Cas9-HDR) promote HDR over NHEJ. - **Cell cycle synchronization** ensures DSB repair in the S/G2 phase for improved HDR.	et al., 2017
Off-Target Effects and Solutions	CRISPR can introduce unintended mutations, leading to potential safety risks. New approaches are being developed to increase precision.	- **High-fidelity Cas9 variants (e.g., Cas9-HF, eSpCas9)** reduce off-target cleavage. - **Truncated guide RNAs (tru-gRNAs)** enhance target specificity. - **Paired nickase strategy (Cas9n)** minimizes unintended DSBs.	Slaymaker et al., 2016; Vakulskas et al., 2018
CRISPR Delivery Methods	Delivery of CRISPR components into target cells remains a challenge, requiring safe and efficient strategies.	- **Viral vectors (AAV, lentivirus)**: High efficiency but potential immunogenicity. - **Lipid nanoparticles (LNPs)**: Safe and widely used in clinical settings. - **Electroporation**: High-efficiency method for ex vivo gene editing.	Miller et al., 2017; Glass et al., 2018
Next-Generation CRISPR Technologies	Advancements beyond CRISPR-Cas9 to improve precision and applicability.	- **CRISPR-Cas12a (Cpf1)**: Smaller enzyme, no need for tracrRNA, improved specificity. - **Base Editing (BE)**: Converts nucleotides without inducing DSBs. - **Prime Editing (PE)**: Directly writes new genetic sequences with minimal errors.	Gaudelli et al., 2017; Komor et al., 2017

b) **Double-Stranded Break Repair Mechanisms**

After introducing a DSB by Cas9, the cell repairs the damage through one of two primary pathways: non-homologous end joining (NHEJ) or homology-directed repair (HDR), NHEJ is an error-prone repair mechanism that directly ligates the broken DNA ends without using a homologous template, often leading to small insertions or deletions (indels), which can disrupt gene function and introduce frameshift mutations (Maruyama et al., 2015; Richardson et al., 2016). This property makes NHEJ particularly useful for gene knockouts, where loss-of-function mutations are desired.

HDR, on the other hand, is a high-fidelity repair mechanism that utilises a homologous DNA template to repair the break accurately. This pathway enables precise gene insertion or replacement and is the preferred mechanism for therapeutic genome editing applications. However, HDR occurs predominantly during the S and G2 phases of the cell cycle, making it less efficient in non-dividing cells (Pinder et al., 2015; Lin et al., 2014). Various strategies are being explored to enhance HDR efficiency, including using small molecules, engineered Cas9 variants, and cell cycle synchronisation techniques to promote HDR-mediated repair over NHEJ (Yu et al., 2015; Bothmer et al., 2017).

Despite its revolutionary potential, CRISPR-Cas9 genome editing is not without challenges. Off-target effects, where Cas9 cleaves unintended genomic sites, remain a significant concern. Efforts to mitigate these effects include the development of high-fidelity Cas9 variants, truncated guide RNAs (tru-gRNAs), and paired nickase strategies (Slaymaker et al., 2016; Vakulskas et al., 2018). Furthermore, immunogenicity and efficient delivery of CRISPR components remain significant hurdles in clinical applications. Researchers are developing safer and more efficient delivery systems, including viral vectors (AAVs, lentiviruses), lipid nanoparticles, and electroporation techniques, to facilitate CRISPR-mediated genome editing in therapeutic settings (Miller et al., 2017; Glass et al., 2018).

The CRISPR-Cas9 system has dramatically transformed the landscape of genetic engineering, offering unprecedented control over DNA modification. However, continued advancements in **Cas9 engineering, repair pathway**

*Corresponding Author: **Sehar Rafique**

modulation, and delivery methods are necessary to fully realise its potential for therapeutic applications (Barrangou & Doudna, 2016; Komor et al., 2017).



Figure 1: DNA Repair Mechanisms After CRISPR-Cas9 Induced Double-Strand Breaks: NHEJ vs. HDR

CRISPR in Human Gene Therapy

a) Gene Editing for Inherited Genetic Disorders

The advent of CRISPR/Cas9 genome editing technology has revolutionised the field of genetic medicine, offering unprecedented precision and efficiency in correcting mutations associated with inherited genetic disorders. The ability of CRISPR/Cas9 to target specific genetic sequences allows for the modification of defective genes responsible for monogenic diseases such as sickle cell anemia, cystic fibrosis, and Duchenne muscular dystrophy. By leveraging the natural DNA repair mechanisms of non-homologous end joining (NHEJ) and homology-directed repair (HDR), CRISPR/Cas9 can introduce beneficial modifications or correct pathogenic mutations (Zhang et al., 2024). The flexibility and efficiency of this technology have led to a surge in research efforts aimed at developing gene therapies for various hereditary conditions, potentially reducing the burden of genetic diseases in affected populations.

Among the key advantages of CRISPR/Cas9 is its ability to induce precise genetic modifications in patient-derived cells. Unlike earlier gene-editing technologies such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), CRISPR/Cas9 offers a more straightforward and more cost-effective approach with higher editing efficiency (Doudna & Charpentier, 2014). This advancement has facilitated significant breakthroughs in developing therapeutic interventions for diseases previously considered untreatable at the genetic level. For instance, researchers have successfully demonstrated the feasibility of using CRISPR/Cas9 to correct mutations in the beta-globin gene responsible for sickle cell disease, offering new hope for patients suffering from this debilitating condition (Mali et al., 2013).

Despite the remarkable progress in gene editing, challenges remain in ensuring the safe and effective delivery of CRISPR components into target cells. Current delivery methods include viral vectors, lipid nanoparticles, and electroporation, each with advantages and limitations. While viral vectors offer efficient gene delivery, concerns about immunogenicity and insertional mutagenesis pose significant barriers to clinical application (Ebina et al., 2013). Additionally, off-target effects, where CRISPR/Cas9 inadvertently modifies unintended genomic sites, remain a significant concern, necessitating the development of high-fidelity Cas9 variants to minimise such risks (Knott & Doudna, 2018). Ongoing research is focused on optimising these delivery strategies and enhancing the specificity of CRISPR-mediated gene editing to ensure the safety and efficacy of future gene therapies.

b) CRISPR Applications in Treating Sickle Cell Anemia and Cystic Fibrosis

Sickle cell anemia and cystic fibrosis are two of the most extensively studied monogenic diseases targeted by CRISPR-based therapies. Sickle cell disease (SCD) results from a single point mutation in the beta-globin gene (HBB), leading to abnormal hemoglobin production and subsequent deformation of red blood cells. This condition causes severe pain, anemia, and organ damage, significantly reducing the quality of life for affected individuals. CRISPR/Cas9 has emerged as a promising therapeutic approach for SCD by correcting the HBB mutation or inducing the expression of fetal hemoglobin (HbF) expression, which can functionally compensate for defective adult hemoglobin (Weber et al., 2020).

Recent clinical trials have demonstrated the potential of CRISPR-based gene therapy in reversing SCD phenotypes. In a landmark study, researchers utilised CRISPR/Cas9 to edit hematopoietic stem cells (HSCs) ex vivo, restoring regular hemoglobin expression before reinfusing the modified cells into patients (Wang et al., 2020). This approach has shown sustained therapeutic benefits, with patients experiencing reduced pain episodes and improved hematological parameters. Furthermore, the absence of significant off-target effects and adverse immune responses underscores the potential of CRISPR-based interventions as a curative treatment for SCD.

Similarly, cystic fibrosis (CF), a life-threatening genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, has become a prime target for CRISPR/Cas9 therapy. The defective CFTR protein leads to the buildup of thick mucus in the lungs and digestive tract, resulting in respiratory complications and reduced life expectancy. CRISPR-mediated correction of CFTR mutations has been successfully demonstrated in vitro and animal models, with ongoing research efforts to develop clinically viable therapies (Seth & Harish, 2016).

One of the primary challenges in CF gene therapy is efficient delivery to lung epithelial cells. While viral vectors have been employed to introduce CRISPR components into airway cells, immune activation and long-term expression concerns limit their clinical utility. Non-viral delivery methods, including lipid nanoparticles and electroporation, are being explored to enhance the safety and efficiency of CRISPR-mediated CFTR correction (Ling et al., 2020). Additionally, researchers are investigating the feasibility of using prime editing. This advanced CRISPR-based technique enables precise single-base substitutions without inducing double-strand breaks, to correct CFTR mutations with greater accuracy and minimal risk of genomic instability (Anzalone et al., 2020).

*Corresponding Author: **Sehar Rafique**

CRISPR in Cancer Treatment (Cancer Immunotherapy)

a) CRISPR for CAR-T Cell Therapy

Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) technology has emerged as a transformative gene-editing tool in cancer immunotherapy, particularly in the development of chimeric antigen receptor T (CAR-T) cell therapy. CAR-T cell therapy is an innovative approach that involves engineering a patient's T cells to recognise and attack cancer cells more effectively. Traditionally, CAR-T cell therapy has been based on viral vector-mediated gene modifications; however, CRISPR/Cas9 offers a more precise, efficient, and cost-effective method for genetic modifications in these cells (Stefanoudakis et al., 2023; Eyquem et al., 2017; Stadtmauer et al., 2020).

One of the significant advantages of using CRISPR for CAR-T therapy is its ability to precisely edit genes that regulate T cell function, thereby enhancing the durability and efficacy of CAR-T cells. For example, PD-1, an immune checkpoint receptor that suppresses T cell activity, has been successfully knocked out using CRISPR to prevent T cell exhaustion, thus improving anti-tumor responses. Clinical trials evaluating PD-1 knockout in CAR-T cells for solid tumors have demonstrated promising preliminary results, with increased persistence of engineered cells in the tumor microenvironment and enhanced tumor clearance (Lu et al., 2020; Liu et al., 2022).

Another critical application of CRISPR in CAR-T cell therapy involves multiplex gene editing to optimise CAR expression and improve resistance to tumor-induced immunosuppression. Several preclinical studies have reported that CRISPR-mediated deletion of genes such as TGF-β receptor and Fas enhances CAR-T cell survival and functionality in hostile tumor microenvironments. Furthermore, using CRISPR to introduce synthetic cytokine genes has been explored to sustain T cell activity and reduce exhaustion (Eyquem et al., 2017; Zhang et al., 2021).

While CRISPR has revolutionised CAR-T cell engineering, its transition to clinical applications has faced challenges such as off-target effects and genomic instability. Researchers are refining CRISPR systems, employing high-fidelity Cas9 variants and base-editing technologies to minimise these risks. The future of CRISPR-based CAR-T therapy appears promising, with ongoing clinical trials investigating various genetic modifications aimed at improving treatment safety and efficacy (Stadtmauer et al., 2020; Frangoul et al., 2021).



Figure 2: ***Procedure to implement adoptive CAR-T cell therapy. This includes the collection of a patient blood sample; T cell selection by leukapheresis from peripheral blood; CAR–gene transfer through a vector; expansion of CAR-T cells in vitro, and re-infusion into the patient.***

b) Editing Immune Cells for Targeted Cancer Therapy

Beyond CAR-T cells, CRISPR has been instrumental in modifying other immune cells for cancer therapy, including natural killer (NK) cells, macrophages, and dendritic cells. The ability to precisely edit genes in these immune cells allows for enhanced tumor recognition, improved persistence, and overcoming immune evasion mechanisms employed by cancer cells (Liu et al., 2020; He et al., 2021).

NK cells, which naturally recognise and kill tumor cells without prior sensitisation, have been genetically modified using CRISPR to improve their cytotoxicity and resistance to immune suppression. For example, CRISPR-mediated knockout of CISH, a negative regulator of cytokine signaling, has been shown to enhance NK cell function against solid tumors. Additionally, researchers have employed CRISPR to improve NK cell persistence by knocking out genes associated with exhaustion, such as TIGIT and TIM-3, which are upregulated in the tumor microenvironment (Romee et al., 2016; He et al., 2021).

Macrophages, a crucial component of the innate immune system, have also been subjected to CRISPR-based modifications to reprogram them from a tumor-promoting (M2) to a tumor-fighting (M1) phenotype. One strategy involves using CRISPR to inhibit the expression of CD47, a 'do not eat me' signal exploited by cancer cells to evade immune clearance. Knockout of CD47 in engineered macrophages enhances their ability to phagocytose cancer cells and stimulates a stronger anti-tumor immune response (Xue et al., 2017; Morrissey et al., 2018).

Dendritic cells, which serve as antigen-presenting cells to activate T cells, have been modified using CRISPR to enhance their ability to prime anti-tumor immunity. Deletion of immune checkpoint molecules such as PD-L1 in dendritic cells has demonstrated improved T cell activation and enhanced tumor-specific immune responses. Additionally, CRISPR has been used to optimise antigen presentation pathways, ensuring more effective recognition of tumor antigens by T cells (Zhou et al., 2020; Burr et al., 2017).

*Corresponding Author: **Sehar Rafique**

The clinical translation of CRISPR-edited immune cells is progressing, with several early-phase clinical trials underway. These trials investigate the safety and efficacy of gene-edited NK cells and macrophages in treating solid tumors, with preliminary results suggesting improved anti-tumor responses and prolonged survival in patients. However, challenges such as potential immunogenicity, scalability of cell manufacturing, and regulatory approval remain critical hurdles that need to be addressed (Frangoul et al., 2021; Stadtmauer et al., 2020).

c) Potential Risks and Future Clinical Trials

Despite its immense potential, CRISPR-based cancer immunotherapy is not without risks. One of the most significant concerns is off-target effects, where unintended genetic modifications may occur, potentially leading to unwanted mutations or genomic instability. Efforts to improve CRISPR specificity, including high-fidelity Cas9 enzymes and base-editing approaches, are currently being explored to mitigate these risks (Anzalone et al., 2020; Kleinstiver et al., 2016).

CRISPR for Infectious Diseases: Potential Risks and Future Clinical Trials

a) CRISPR Applications Against Viral Infections (HIV, HPV, SARS-CoV-2)

CRISPR technology has shown immense potential in targeting viral infections, particularly persistent and pandemic-causing viruses such as human immunodeficiency virus (HIV), human papillomavirus (HPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As an adaptive immune system in bacteria, CRISPR-Cas systems can be harnessed to disrupt viral genomes, thus eliminating viral replication and persistence in infected hosts (Strich & Chertow, 2019).

HIV remains a major global health challenge due to its integration into the host genome, rendering it incurable through conventional antiretroviral therapies. CRISPR-Cas9 has been explored as a potential strategy to excise integrated HIV-1 proviral DNA from host cells. Studies have demonstrated that using CRISPR-Cas9 to target long terminal repeats (LTRs) of the HIV genome successfully removed viral sequences in infected cells, offering a promising approach for HIV cure research (Hu et al., 2014; Yin et al., 2017). Despite these advances, off-target effects and viral escape mutations remain key challenges, necessitating further optimisation of CRISPR-based anti-HIV therapies (Strich & Chertow, 2019).

For HPV, CRISPR has been explored as a means to target and eliminate the E6 and E7 oncogenes, which are responsible for HPV-induced carcinogenesis. Studies using CRISPR-Cas9 to edit these genes in HPV-positive cells resulted in apoptosis and restoration of p53 function, suggesting a novel therapeutic strategy for HPV-associated cancers (Kennedy et al., 2014). However, challenges related to delivery efficiency and potential immune responses must be addressed before clinical application (Strich & Chertow, 2019).

During the COVID-19 pandemic, CRISPR-Cas systems were rapidly adapted for diagnostics and potential therapeutics. CRISPR-based antiviral approaches, such as Cas13-mediated degradation of SARS-CoV-2 RNA, have shown promise in preclinical studies. The SHERLOCK and DETECTR platforms, which use Cas12 and Cas13 enzymes, have been employed for rapid and specific SARS-CoV-2 detection, reducing the reliance on traditional RT-PCR methods (Gootenberg et al., 2017; Chen et al., 2018). However, CRISPR therapeutics for SARS-CoV-2 are still in experimental stages, requiring further validation through clinical trials (Strich & Chertow, 2019).

b) CRISPR-Based Diagnostics for Infectious Diseases

The ability of CRISPR to accurately detect nucleic acid sequences has revolutionised infectious disease diagnostics. CRISPR-based diagnostics leverage Cas12 and Cas13 enzymes, which exhibit collateral cleavage activity upon target recognition, enabling signal amplification for highly sensitive detection of pathogens (Strich & Chertow, 2019).

One of the most significant applications is the development of the SHERLOCK and DETECTR systems, which utilise Cas13 and Cas12, respectively, to identify viral and bacterial pathogens. These methods have been successfully employed for detecting Zika, Dengue, Mycobacterium tuberculosis, and SARS-CoV-2 with high sensitivity and specificity (Kellner et al., 2019). Unlike conventional PCR-based diagnostics, CRISPR-based methods do not require sophisticated laboratory infrastructure, making them highly useful for point-of-care testing in resource-limited settings (Myhrvold et al., 2018).

Furthermore, CRISPR has been applied to antimicrobial resistance (AMR) detection, enabling rapid identification of resistance genes in bacterial pathogens. Studies have demonstrated that CRISPR-Cas9 combined with optical DNA mapping can accurately detect antibiotic resistance genes, offering a new approach to combat the growing threat of AMR (Müller et al., 2016). However, standardisation, regulatory approvals, and large-scale implementation must be addressed before these technologies can be widely adopted in clinical practice (Strich & Chertow, 2019).



Figure 3: ***CRISPR-Based Diagnosis of Infectious and Noninfectious Diseases***

c) Prospects for Personalized Medicine in Virology

The emergence of CRISPR-based technologies has paved the way for personalised medicine in virology, offering patient-specific treatments for infectious diseases. The ability to edit

*Corresponding Author: **Sehar Rafique**

viral genomes and host factors critical for viral replication enables the development of targeted therapies tailored to individual patients (Strich & Chertow, 2019).

One of the most promising applications is the use of CRISPR for personalised antiviral therapies against chronic infections such as HIV and hepatitis B virus (HBV). CRISPR has been used to target integrated HBV DNA, effectively reducing viral loads in infected hepatocytes. While these findings are encouraging, completely eradicating latent HBV reservoirs remains a significant hurdle (Li et al., 2018). Future research aims to refine CRISPR editing strategies and delivery methods to improve therapeutic efficacy and minimise unintended genomic alterations (Strich & Chertow, 2019).

Another avenue in personalised virology is the development of CRISPR-based immune cell engineering. For instance, CRISPR-edited T cells have been explored to enhance immune responses against viral infections. In a clinical trial, CRISPR disrupted the CCR5 gene in human T cells, making them resistant to HIV infection (Xu et al., 2019). This approach has shown promise for HIV cure strategies but requires further validation to ensure long-term safety and efficacy (Strich & Chertow, 2019).

Despite CRISPR's potential in personalised medicine, several challenges must be overcome before its clinical application. These include ethical concerns, potential off-target effects, immune responses to CRISPR components, and regulatory hurdles (Hsu et al., 2014). Future research should focus on improving CRISPR specificity, developing non-viral delivery systems, and conducting rigorous clinical trials to establish safety and efficacy (Strich & Chertow, 2019).

CRISPR in Agriculture and Crop Improvement (Genome Editing in Plants)

a) Improving Crop Yield and Resistance to Pests and Diseases

The application of CRISPR-Cas9 in agriculture has significantly advanced the ability to improve crop yield and resistance to pests and diseases. By enabling precise genome editing, CRISPR allows the modification of genes responsible for plant growth, yield potential, and pathogen resistance (Arora & Narula, 2017). One of the most critical applications of CRISPR in agriculture is the development of pest-resistant crops, reducing the dependency on chemical pesticides that can harm ecosystems and human health. For instance, CRISPR has been used to target genes involved in susceptibility to fungal infections, such as OsERF922 in rice, leading to enhanced resistance to blast disease (Wang et al., 2016). Similarly, CRISPR-mediated mutations in the MLO (mildew resistance locus) genes in wheat have successfully conferred resistance to powdery mildew, one of the most devastating fungal diseases affecting cereal crops (Wang et al., 2014).

Besides pathogen resistance, CRISPR technology has enhanced crop yield by modifying genes associated with growth and productivity. Studies have demonstrated that genome-editing tools can improve grain number, seed size, and plant architecture in crops such as rice and maise. For example, CRISPR-mediated edits to the Gn1a, DEP1, and GS3 genes in rice have significantly increased yield by optimizing panicle architecture and grain development (Li et al., 2016). Furthermore, CRISPR has been employed to engineer resistance to insect pests by modifying plant defense mechanisms. In cotton, targeting genes involved in synthesising gossypol, a natural insect deterrent, has improved resistance to bollworms while maintaining fiber quality (Chen et al., 2017).

While CRISPR is promising to improve agricultural productivity, challenges such as off-target mutations and regulatory hurdles remain. Advances in high-fidelity Cas9 variants and base-editing technologies aim to minimise unintended modifications, enhancing the precision and safety of CRISPR-based crop improvement (Arora & Narula, 2017).

b) CRISPR-Modified Crops for Climate Resilience

The increasing impact of climate change on global food security has necessitated the development of crops with enhanced resilience to extreme environmental conditions. CRISPR-Cas9 has emerged as a powerful tool for engineering climate-resilient crops by modifying genes that regulate drought tolerance, salinity resistance, and temperature adaptation (Arora & Narula, 2017). For example, CRISPR has been used to target genes such as OsNAC14 and OsDREB1 in rice, improving drought resistance and water-use efficiency (Gao et al., 2020). Similarly, genome editing of the SlMAPK3 gene in tomato has enhanced tolerance to high temperatures, demonstrating the potential of CRISPR in mitigating the adverse effects of climate change on crop production (Wang et al., 2021).

Soil salinity is another major constraint affecting crop yields, particularly in arid and semi-arid regions. CRISPR has been successfully applied to modify genes involved in salt stress responses, such as SOS1 and NHX1 in wheat and rice, leading to enhanced salt tolerance and improved crop survival under saline conditions (Zhou et al., 2020). Furthermore, CRISPR has been utilised to alter gene expression in root architecture, enabling plants to access deeper water reserves during prolonged droughts. This has been demonstrated in maise and soybean, where targeted modifications to the ROOT and DRO1 genes have resulted in deeper root systems and improved drought resilience (Uga et al., 2013).

In addition to abiotic stress tolerance, CRISPR has facilitated the development of crops that can thrive in nutrient-poor soils. Researchers have created crops that require less fertiliser while maintaining high yields by editing genes involved in nitrogen use efficiency, such as NRT1.1B in rice (Li et al., 2018). This benefits farmers by reducing input costs and contributes to sustainable agricultural practices by minimising the environmental impact of excessive nitrogen fertilisation (Arora & Narula, 2017).

Despite the promise of CRISPR in climate resilience, concerns about the long-term stability of edited traits and potential ecological impacts remain. Ongoing research is focused on refining gene-editing techniques and conducting

*Corresponding Author: **Sehar Rafique**

extensive field trials to ensure the reliability and safety of CRISPR-modified crops before widespread commercial adoption (Zhou et al., 2020).

c) Regulatory Frameworks for GMOs and Consumer Concerns

The regulatory landscape surrounding CRISPR-modified crops remains a topic of global debate, with policies varying significantly between countries. Unlike traditional genetically modified organisms (GMOs), which involve the insertion of foreign DNA, CRISPR-edited crops often contain minor, precise modifications that mimic natural mutations. As a result, regulatory agencies in some countries, such as the United States and Japan, have classified CRISPR-edited crops differently from transgenic GMOs, streamlining their approval process (Arora & Narula, 2017). In contrast, the European Union maintains stringent regulations, treating genome-edited crops under the same regulatory framework as conventional GMOs, which has slowed their adoption (Eckerstorfer et al., 2019).

One of the major concerns surrounding CRISPR-modified crops is consumer acceptance. Public perception of genetically edited foods is influenced by factors such as perceived risks, ethical considerations, and the transparency of regulatory oversight. Surveys indicate that consumers are more likely to accept genome-edited crops if they are presented as an extension of traditional breeding rather than as artificial genetic modifications (Shew et al., 2018). Educational initiatives and clear labeling policies can address public concerns and promote informed decision-making regarding CRISPR-based agricultural innovations (Arora & Narula, 2017).

In addition to regulatory and consumer concerns, intellectual property rights and market access pose challenges for CRISPR-modified crops. The patent landscape for CRISPR technology is highly complex, with multiple entities holding key patents on Cas9 and related gene-editing tools. This has raised concerns about accessibility and affordability, particularly for small-scale farmers in developing countries (Shan et al., 2020). Efforts to create open-access CRISPR platforms and public-sector breeding programs are essential to ensure equitable distribution of genome-editing technologies (Arora & Narula, 2017).

As CRISPR-based plant breeding continues to evolve, regulatory frameworks must balance innovation with safety considerations. Harmonising global policies and fostering transparent scientific communication will facilitate the responsible adoption of CRISPR-modified crops while addressing ethical and socio-economic concerns (Eckerstorfer et al., 2019).

CRISPR and Livestock Biotechnology (Animal Genetics)

a) CRISPR Applications in Livestock Breeding

CRISPR-Cas9 technology has revolutionised livestock breeding by allowing precise genome editing to enhance desirable traits such as growth rate, reproductive efficiency, and meat quality. Traditional breeding methods, which rely on selective mating, have limitations due to long generational intervals and genetic variability. CRISPR circumvents these challenges by directly modifying genes responsible for productivity and efficiency (Jabbar et al., 2021). For example, the myostatin (MSTN) gene, which negatively regulates muscle growth, has been successfully knocked out in cattle, sheep, and pigs to produce animals with increased muscle mass and improved meat yield (Proudfoot et al., 2015). This modification has significantly improved meat quality without adverse effects on animal health.

In dairy cattle, CRISPR-mediated edits to the prolactin receptor (PRLR) and casein genes have been explored to enhance milk production and composition. Modifying the beta-casein gene has improved milk protein content, which is beneficial for cheese production and human digestion (Van Eenennaam, 2019). Additionally, the polled (hornless) trait in cattle, which traditionally required dehorning to prevent injuries, has been successfully introduced using CRISPR by editing the POLLED gene (Carlson et al., 2016). This advancement eliminates the need for painful dehorning procedures, improving animal welfare.

Despite these promising applications, challenges such as potential off-target effects, genetic mosaicism, and regulatory hurdles must be addressed. Continuous research is being conducted to refine CRISPR technology, ensuring higher precision and minimising unintended genetic modifications (Jabbar et al., 2021).

b) Disease Resistance in Farm Animals Through Gene Editing

One of the most significant applications of CRISPR in livestock is the development of disease-resistant animals. Infectious diseases such as porcine reproductive and respiratory syndrome virus (PRRSV), bovine tuberculosis, and avian influenza pose significant threats to global livestock industries. CRISPR-based genetic modifications offer a powerful tool to enhance resistance to these diseases, reducing the need for antibiotics and vaccines (Jabbar et al., 2021).

For instance, researchers have successfully knocked out the CD163 receptor in pigs, rendering them resistant to PRRSV, a disease that causes severe economic losses in the swine industry. Studies have shown that CD163-edited pigs exhibit no adverse effects and remain fully resistant to the virus, making this a promising strategy for improving swine health (Whitworth et al., 2015). Similarly, the NRAMP1 gene, which plays a critical role in immune response, has been introduced into cattle to enhance resistance to bovine tuberculosis, a zoonotic disease affecting livestock and humans (Gao et al., 2017).

CRISPR has been used in poultry to modify genes associated with avian influenza resistance. By targeting ANP32A, a gene required for viral replication, researchers have developed chickens that are less susceptible to infection (Lyall et al., 2011). This approach protects poultry populations and minimises the risk of zoonotic transmission to humans, contributing to global public health efforts.

*Corresponding Author: **Sehar Rafique**

While CRISPR-based disease resistance presents exciting opportunities, concerns about long-term genetic stability and unintended consequences remain. Regulatory agencies are closely monitoring these developments to ensure the safety and effectiveness of gene-edited livestock before widespread commercial adoption (Jabbar et al., 2021).

c) Ethical Concerns in Animal Genome Modification

Using CRISPR for genetic modification in livestock raises several ethical considerations, particularly regarding animal welfare, genetic diversity, and public perception. While genome editing offers potential benefits, such as improved health and productivity, concerns about unintended consequences and long-term effects on animal populations persist (Jabbar et al., 2021).

One primary ethical debate surrounds the potential for unintended suffering in genetically modified animals. While CRISPR is designed to enhance desirable traits, some modifications may inadvertently result in unforeseen health issues. For example, altering genes associated with muscle growth could increase stress on the skeletal system, potentially affecting mobility and overall well-being (Proudfoot et al., 2015). Ethical frameworks must consider the welfare implications of genetic modifications to ensure that animal health is not compromised in pursuit of agricultural benefits.

Another concern is the impact of CRISPR on genetic diversity. The widespread use of specific genetic modifications could reduce genetic variation within livestock populations, making them more vulnerable to emerging diseases and environmental changes (Van Eenennaam, 2019). Conservation strategies should be implemented to maintain genetic diversity while leveraging the benefits of genome editing.

Public perception and consumer acceptance also play a crucial role in adopting CRISPR-modified livestock. While genetically edited animals differ from traditional genetically modified organisms (GMOs) that incorporate foreign DNA, many consumers remain hesitant about the technology. Transparent communication and rigorous regulatory oversight are essential to addressing consumer concerns and ensuring the ethical deployment of CRISPR in livestock breeding (Jabbar et al., 2021).

Table: ***Applications of CRISPR in Agriculture and Crop Improvement***

Category	Key Applications	Target Genes	Examples and Outcomes	References
Improving Crop Yield and Resistance to Pests and Diseases	Enhancing disease resistance	*OsERF922* (Rice)	CRISPR-edited rice showed enhanced resistance to *Magnaporthe oryzae* (rice blast disease), reducing yield losses.	Wang et al., 2016
	Resistance to powdery mildew	*MLO* (Wheat, Barley)	Mutations in *MLO* genes conferred strong resistance to powdery mildew in wheat and barley without compromising plant growth.	Wang et al., 2014; Acevedo-Garcia et al., 2017
	Bacterial blight resistance	*Xa23*, *SWEET* genes (Rice)	Targeting *SWEET* transporters improved bacterial blight resistance in rice.	Oliva et al., 2019
	Virus resistance	*eIF4E* (Tomato, Cucumber)	CRISPR-modified tomato and cucumber showed resistance to potyviruses by altering *eIF4E* gene function.	Pyott et al., 2016
	Insect pest resistance	*Gossypol synthesis genes* (Cotton)	Increased resistance to bollworms while maintaining fiber quality.	Chen et al., 2017
	Improving grain yield and size	*Gn1a*, *DEP1*, *GS3*, *GW2* (Rice, Maize)	Increased panicle architecture, grain number, and seed size, enhancing yield.	Li et al., 2016; Zhang et al., 2018
	Herbicide resistance	*ALS*, *EPSPS* (Soybean, Maize)	CRISPR-induced mutations conferred resistance to glyphosate-based herbicides, improving weed management.	Li et al., 2020
	Biofortification (Nutrient enhancement)	*VIT1*, *ZIP4* (Rice, Wheat)	CRISPR-engineered crops showed increased iron and zinc content, addressing malnutrition concerns.	Zhang et al., 2019
CRISPR-Modified Crops for Climate	Drought tolerance	*OsNAC14*, *OsDREB1*, *ERF*	Enhanced water-use efficiency and drought resistance in cereals by altering stress-	Gao et al., 2020; Shinozaki et al.,

*Corresponding Author: **Sehar Rafique**

Resilience		(Rice, Wheat)	responsive genes.	2018
	Heat tolerance	*SlMAPK3*, *HSP* (Tomato, Arabidopsis)	Improved temperature resilience under heat stress by modifying heat-shock proteins and signaling pathways.	Wang et al., 2021; Ohama et al., 2017
	Salinity resistance	*SOS1*, *NHX1*, *HKT1* (Wheat, Rice, Tomato)	Increased survival and yield in saline environments by enhancing sodium ion homeostasis.	Zhou et al., 2020; Zhang et al., 2021
	Root system modification for drought adaptation	*ROOT*, *DRO1*, *PSTOL1* (Maize, Soybean, Rice)	Deeper root growth enabled better water uptake, improving resilience in dry conditions.	Uga et al., 2013; Gamuyao et al., 2012
	Nitrogen-use efficiency	*NRT1.1B*, *DELLAs* (Rice, Wheat, Maize)	Improved nitrogen uptake, allowing for high crop productivity with reduced fertilization.	Li et al., 2018; Wang et al., 2019
	Cold tolerance	*CBF*, *ICE1* (Wheat, Tomato)	CRISPR-modified plants exhibited improved cold tolerance through the regulation of cold-responsive transcription factors.	Ding et al., 2018
	Flood tolerance	*SUB1A* (Rice)	Genome-edited rice varieties maintained growth under submergence conditions.	Xu et al., 2006
Regulatory Frameworks and Consumer Concerns	GMO classification and approval	Policy differences across USA, EU, Japan, China	The USA and Japan classify CRISPR-edited crops as non-GMO, while the EU follows stricter GMO regulations. China is actively developing CRISPR policies to facilitate commercialization.	Eckerstorfer et al., 2019; Huang et al., 2021
	Public perception and acceptance	Ethical and safety concerns	Consumer acceptance is influenced by perceived risks, transparency, and education. Public outreach and regulatory clarity improve acceptance.	Shew et al., 2018
	Intellectual property and accessibility	Patent restrictions on CRISPR technology	Complex CRISPR patent landscape limits accessibility. Open-source initiatives are needed for equitable agricultural benefits.	Shan et al., 2020
	Bioethics and environmental concerns	Off-target mutations and ecological impact	High-fidelity CRISPR variants (e.g., Cas12a, base-editing) reduce unintended mutations, increasing biosafety.	Gaudelli et al., 2017
	Market access for developing nations	Cost and seed sovereignty	CRISPR-modified crops must be affordable for smallholder farmers. Public-sector breeding initiatives are essential.	Arora & Narula, 2017

CRISPR and Synthetic Biology (Synthetic Biology)

a) Engineering New Biological Pathways with CRISPR

CRISPR-Cas systems have transformed synthetic biology by enabling precise modifications in metabolic and genetic pathways to optimise biological functions. The ability to introduce targeted genetic changes has facilitated the design of synthetic gene circuits, allowing the creation of programmable biological systems (Jeong et al., 2023). By engineering these pathways, researchers have enhanced biosynthetic capabilities in microorganisms, leading to improved production of valuable metabolites, bioactive compounds, and pharmaceuticals.

One of the key applications of CRISPR in pathway engineering is the optimisation of microbial metabolism. Microorganisms such as Escherichia coli and Saccharomyces cerevisiae have been engineered using CRISPR-Cas9 to enhance the biosynthesis of therapeutic compounds such as artemisinic acid, an essential precursor for malaria treatment (Ro et al., 2006). Similarly, CRISPR has been employed to reprogram metabolic flux in Corynebacterium glutamicum to increase the production of amino acids like lysine, which is widely used in the food and pharmaceutical industries (Jeong et al., 2023).

Beyond microbial applications, CRISPR-mediated pathway modifications have been applied to plants to improve secondary metabolite production. For example, targeted edits

*Corresponding Author: **Sehar Rafique**

in the flavonoid biosynthesis pathway in Nicotiana tabacum have led to increased antioxidant properties, highlighting CRISPR's potential in agricultural biotechnology (Zhou et al., 2020). Additionally, CRISPR has facilitated the engineering of bacterial and fungal strains for bioremediation applications, enabling the efficient degradation of environmental pollutants such as plastics and hydrocarbons (Nielsen & Keasling, 2016).

While CRISPR has advanced pathway engineering, challenges like off-target effects and unintended mutations persist. Researchers have developed high-fidelity Cas variants and base-editing approaches to mitigate these issues, thereby improving precision and stability in engineered pathways (Jeong et al., 2023). Future advancements in synthetic biology will continue to refine CRISPR-mediated metabolic engineering for industrial and medical applications.

b) Synthetic Genomes and Bioengineering Applications

Developing synthetic genomes is a groundbreaking aspect of synthetic biology, and CRISPR plays a crucial role in refining genome construction and modification. Synthetic biology aims to create de novo organisms with customised genetic features, enhancing their functionality for medical, agricultural, and industrial applications (Jeong et al., 2023). CRISPR-Cas9 has significantly improved genome editing efficiency, allowing precise alterations in synthetic genomes to optimise cellular behaviour.

A landmark achievement in synthetic genome research was the creation of a fully functional synthetic bacterial genome for Mycoplasma mycoides. This work demonstrated the feasibility of designing and constructing entirely synthetic organisms, paving the way for programmable life forms (Gibson et al., 2010). CRISPR technology has been used to further refine synthetic genomes by enabling multiplexed gene edits, enhancing adaptability and robustness in engineered cells (Doudna & Charpentier, 2014).

Synthetic genome approaches have also been applied to yeast, where CRISPR has facilitated the systematic rewriting of chromosomes to optimise biofuel and pharmaceutical production. In the Synthetic Yeast Genome Project (Sc2.0), researchers used CRISPR to introduce novel genetic elements that improved yeast fermentation efficiency, demonstrating the potential of CRISPR in industrial bioengineering (Richardson et al., 2017).

Another critical area of synthetic genome engineering is the creation of artificial genetic circuits that mimic natural cellular processes. CRISPR-based circuits have been developed to regulate gene expression dynamically, enabling precise control over cellular functions. These circuits have applications in medical biotechnology, including developing programmable immune cells for targeted cancer therapies (Jeong et al., 2023).

Despite these advancements, ethical concerns and biosafety issues surrounding synthetic genomes remain. The potential risks of creating entirely synthetic organisms include ecological impacts and unforeseen mutations. Regulatory guidelines are being established to ensure the responsible development and deployment of CRISPR-based synthetic genome technologies (Doudna & Charpentier, 2014).

c) CRISPR in Biomanufacturing and Biofuel Production

CRISPR technology has transformed biomanufacturing, particularly in producing sustainable biofuels and bioproducts. Traditional biofuel production has relied on genetically modified microorganisms, but CRISPR provides a more precise and efficient approach to optimising microbial metabolism for biofuel generation (Jeong et al., 2023). By targeting key genes involved in metabolic pathways, CRISPR enhances fermentation efficiency, lipid biosynthesis, and biomass conversion.

One primary application of CRISPR in biomanufacturing is the engineering of Saccharomyces cerevisiae and Clostridium acetobutylicum for bioethanol and biobutanol production. By modifying genes that regulate carbon metabolism, researchers have improved sugar utilisation and alcohol yield during fermentation processes (Liao et al., 2016). Similarly, CRISPR has enhanced lipid biosynthesis pathways in algae such as Chlamydomonas reinhardtii, increasing bio-oil production for biodiesel applications (Jiang et al., 2021).

Beyond biofuels, CRISPR has enabled the development of microbial cell factories to produce bioplastics, pharmaceuticals, and industrial enzymes. For example, Cupriavidus necator has been engineered using CRISPR to enhance polyhydroxyalkanoate (PHA) production, a biodegradable plastic alternative to petroleum-based plastics (Jeong et al., 2023). Additionally, CRISPR has been employed to optimise enzyme production in bacteria, facilitating more efficient industrial biocatalysis for chemical synthesis.

Despite its potential, CRISPR-driven biomanufacturing faces challenges such as metabolic burden on engineered microbes, regulatory constraints, and public perception issues. Researchers are actively working on strategies to optimise CRISPR editing efficiency, integrate synthetic biology tools for fine-tuned metabolic regulation, and improve public acceptance of CRISPR-based bioproducts (Nielsen & Keasling, 2016).



Figure: CRISPR Applications in Synthetic Biology

*Corresponding Author: **Sehar Rafique**

CRISPR in Neurodegenerative Diseases (CRISPR in Neurology)

a) Potential for Treating Alzheimer's and Parkinson's Disease

Neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) pose significant challenges due to their progressive nature and lack of curative treatments. CRISPR-Cas9 has emerged as a promising tool for gene editing in neurology, providing avenues for correcting genetic mutations, regulating disease-related pathways, and developing patient-specific cell models (Sen & Thummer, 2022). The ability of CRISPR to introduce precise genetic modifications makes it an attractive approach for treating these disorders at their molecular roots.

Alzheimer's disease is characterised by the accumulation of amyloid-beta plaques and tau tangles, leading to neuronal degeneration. Several genes, including *APP* (amyloid precursor protein), *PSEN1*, and *PSEN2*, have been implicated in AD pathology. CRISPR has been successfully used to correct mutations in these genes in patient-derived induced pluripotent stem cells (iPSCs), demonstrating its potential for gene therapy (Wang et al., 2018). Moreover, CRISPR interference (CRISPRi) has been employed to suppress *BACE1*, a key enzyme in amyloid-beta production, reducing amyloid deposition in neuronal models (Zhou et al., 2020). These findings suggest that CRISPR could be a powerful tool for modifying disease progression at the genetic level.

Similarly, Parkinson's disease involves the loss of dopaminergic neurons in the substantia nigra, mainly due to mutations in genes such as *LRRK2*, *PINK1*, and *SNCA*. CRISPR-Cas9 has been applied to correct LRRK2 mutations in patient-derived iPSCs, restoring normal cellular function in dopaminergic neurons (Chen et al., 2019). CRISPR-based gene repression has also been used to reduce alpha-synuclein aggregation, a key pathological feature of PD (Soldner et al., 2016). These interventions provide a foundation for future gene therapies to mitigate disease progression.

Despite these advancements, translating CRISPR-based therapies to clinical applications faces significant hurdles, including challenges in delivery, potential off-target effects, and immune responses (Sen & Thummer, 2022). Ongoing research aims to refine CRISPR precision and develop safe, efficient delivery mechanisms for neural gene editing.



Figure 4: ***CRISPR-Cas9 Applications in Neurology: Gene Editing for Alzheimer's and parkinson Disease. (Bhardwaj et al., 2022)***

b) Challenges in Targeting Neural Cells

One of the primary challenges in applying CRISPR to neurodegenerative diseases is delivering gene-editing components across the blood-brain barrier (BBB). The BBB acts as a selective filter, preventing the entry of foreign molecules into the brain, which complicates the efficient delivery of CRISPR-Cas9 systems to neural cells (Sen & Thummer, 2022). To address this issue, researchers are exploring viral and non-viral delivery methods. While adeno-associated viruses (AAVs) are commonly used for CRISPR delivery, they have limitations, including immune responses and restricted cargo capacity (Li et al., 2021). Alternative approaches such as lipid nanoparticles and exosome-based delivery systems are being investigated to improve CRISPR efficiency and reduce immunogenicity (Miller et al., 2020).

Another challenge lies in ensuring precise gene editing while minimising off-target effects. The nervous system is susceptible to genetic perturbations, and unintended modifications could lead to adverse outcomes, including neuronal toxicity and functional impairments. Advances in high-fidelity Cas enzymes, such as Cas9-HF1 and base-editing systems, have improved CRISPR specificity, reducing the likelihood of unintended mutations (Kleinstiver et al., 2016).

Additionally, the heterogeneity of neurodegenerative diseases complicates the development of universal CRISPR-based therapies. AD and PD exhibit diverse genetic and environmental influences, necessitating personalised approaches tailored to individual patient profiles. CRISPR-mediated iPSC models have facilitated the study of patient-specific genetic variants, paving the way for personalised gene-editing therapies (Sen & Thummer, 2022).

c) Ethical and Safety Concerns in Neural Gene Editing

The use of CRISPR for neurodegenerative diseases raises critical ethical and safety concerns, particularly regarding the potential for unintended genetic modifications, long-term consequences of gene editing, and human enhancement and genetic privacy issues. Given the irreversible nature of CRISPR-based modifications in the nervous system, ethical guidelines must be established to govern its application (Sen & Thummer, 2022).

One of the foremost ethical concerns is the potential for germline editing. While CRISPR therapies for neurodegenerative diseases focus primarily on somatic cell editing, unintended germline modification risks remain contentious. Regulatory bodies such as the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) emphasise the need for strict oversight and ethical considerations in human gene editing research (NASEM, 2017).

*Corresponding Author: **Sehar Rafique**

Another primary concern is the long-term safety of CRISPR-based therapies. The nervous system's complexity makes it difficult to predict the full impact of gene-editing interventions, raising questions about potential unintended consequences. Studies have highlighted the risk of immune responses to CRISPR components, mainly when delivered via viral vectors (Li et al., 2021). Addressing these concerns requires extensive preclinical testing and the development of safer, transient gene-editing methods.

Finally, societal and ethical implications of CRISPR in neurology extend beyond safety and regulatory considerations. Public perception of gene editing in the brain remains a significant challenge, with concerns about genetic determinism, consent in vulnerable populations, and potential misuse of the technology for cognitive enhancement. Transparent communication and ethical frameworks must be established to ensure responsible research and application of CRISPR in neurodegenerative disease treatment (Sen & Thummer, 2022).

Challenges and Limitations of CRISPR (CRISPR Limitations)

a) Off-Target Effects and Unintended Mutations

CRISPR-Cas9 technology has revolutionised genetic editing, offering unprecedented precision in modifying specific DNA sequences. However, one of its most significant limitations is the occurrence of off-target effects, where the Cas9 enzyme cleaves unintended genomic sites, leading to unpredictable genetic mutations (Chehelgerdi et al., 2024). These off-target effects can result in genomic instability, potentially leading to deleterious consequences such as tumorigenesis or impaired cellular functions.

Several studies have demonstrated that CRISPR-Cas9 can generate unintended mutations due to the presence of highly similar sequences in the genome. For example, unintended cleavage at sites resembling the intended target has been observed in cancer cells and neuronal models, raising concerns about its applicability in gene therapy (Zhang et al., 2019). To mitigate this risk, researchers have developed high-fidelity Cas9 variants, such as Cas9-HF1 and eSpCas9, which exhibit reduced off-target activity while maintaining high editing efficiency (Kleinstiver et al., 2016). Nevertheless, ensuring absolute specificity remains challenging, particularly in therapeutic settings where minimal off-target modifications could have severe consequences.

Another approach to minimise off-target effects involves using base editors, which modify single nucleotides without inducing double-strand breaks (Gaudelli et al., 2017). Base editing has shown promise in correcting point mutations associated with genetic disorders; however, concerns remain regarding its precision and potential for unintended modifications. Guide RNA (gRNA) modifications, such as truncated gRNAs or chemically stabilised variants, have been explored to enhance target specificity and reduce erroneous cleavage events (Kim et al., 2020).

Despite these advancements, comprehensive off-target assessment methods are necessary before CRISPR can be widely adopted in clinical applications. Whole-genome sequencing and bioinformatics tools are being employed to evaluate off-target mutations systematically. However, challenges persist in accurately predicting and mitigating these effects across different cell types and genetic backgrounds (Chehelgerdi et al., 2024). Ongoing research aims to refine computational models and develop more sophisticated screening techniques to enhance the safety profile of CRISPR-based therapies.



Figure: *Navigating CRISPR Challenges and solutions*

b) Technical and Safety Challenges in Clinical Applications

The transition of CRISPR from laboratory research to clinical applications presents several technical and safety challenges. One primary concern is the efficiency and reliability of CRISPR-mediated gene edits in human cells. Variability in gene-editing outcomes has been observed across different tissue types, influenced by chromatin accessibility, cellular repair mechanisms, and individual genetic variations (Chehelgerdi et al., 2024). These inconsistencies pose challenges for achieving uniform therapeutic effects in patients.

Another critical issue is the potential for immune responses against CRISPR components. The Cas9 enzyme, derived from bacteria such as *Streptococcus pyogenes* and *Staphylococcus aureus*, can elicit an immune reaction when introduced into human cells (Wagner et al., 2019). Studies have reported the presence of pre-existing antibodies against Cas9 proteins in human serum, which could compromise the efficacy of CRISPR-based therapies and lead to adverse immunological reactions. Strategies such as transient expression of Cas9 via mRNA delivery and engineered Cas9 variants with reduced immunogenicity are being explored to address this concern (Kim et al., 2021).

In addition to immune responses, the long-term stability of CRISPR edits remains an open question. While some genetic modifications are intended to be permanent, others may require transient regulation to prevent unintended consequences. Epigenetic modifications and cellular repair pathways can influence the persistence of CRISPR-induced

*Corresponding Author: **Sehar Rafique**

changes, leading to variability in therapeutic outcomes (Chehelgerdi et al., 2024). Researchers are investigating inducible CRISPR systems and reversible gene-editing approaches to enhance the control and safety of genetic interventions.

Moreover, ethical considerations and regulatory barriers further complicate the clinical adoption of CRISPR technology. Concerns regarding the potential misuse of gene-editing tools for human enhancement or germline modifications have led to strict regulatory scrutiny in many countries (Greely, 2019). While somatic gene editing is gaining acceptance for treating genetic disorders, the ethical implications of editing heritable traits remain a topic of intense debate. Establishing standardised guidelines and ethical frameworks will be crucial in navigating the complexities of CRISPR-based clinical applications.



Figure 5: Overcoming CRISPR Limitations: Addressing Off-Target Effects, Safety Concerns, and Delivery Challenges. (Rasul et al., 2022)

c) Need for Improved Gene Delivery Systems

Efficient and targeted delivery of CRISPR components to specific cells and tissues is a significant hurdle in gene-editing applications. Traditional delivery methods, including viral vectors and lipid nanoparticles, have limitations in terms of safety, specificity, and long-term stability (Chehelgerdi et al., 2024). Adeno-associated viruses (AAVs) are commonly used for CRISPR delivery due to their ability to transduce a wide range of cell types; however, their limited cargo capacity and immunogenicity potential pose therapeutic applications challenges (Doudna & Charpentier, 2014).

Lipid nanoparticles (LNPs) have emerged as a promising alternative for CRISPR delivery, particularly for in vivo applications. LNP-based delivery systems have successfully transported mRNA-encoded Cas9 and gRNA to target tissues, offering a non-viral and transient approach to gene editing (Liu et al., 2020). However, challenges related to tissue specificity, stability, and potential off-target effects of LNP formulations must be addressed before widespread clinical implementation.

Another approach involves using extracellular vesicles, such as exosomes, which can facilitate targeted CRISPR delivery with reduced immunogenicity. Exosome-mediated delivery has shown promise in preclinical models for delivering gene-editing components to neural and cardiac tissues, highlighting its potential for therapeutic applications (Chehelgerdi et al., 2024). Further research is needed to optimise exosome engineering and improve loading efficiency for clinical use.

Physical methods, such as electroporation and microinjection, have also been explored for delivering CRISPR constructs directly into cells. While these techniques offer high efficiency in vitro, their applicability in vivo is limited due to tissue damage and low transfection rates (Ramakrishna et al., 2014). Hybrid delivery approaches that combine multiple strategies, such as nanoparticle-based electroporation or targeted peptide carriers, are being developed to enhance CRISPR delivery efficiency while minimising adverse effects.

Ultimately, the success of CRISPR-based therapies will depend on the development of safe, efficient, and targeted gene delivery systems. Advances in nanotechnology, synthetic biology, and biomaterials will play a crucial role in overcoming current delivery challenges and unlocking the full potential of CRISPR for clinical applications.

Future Perspectives and Conclusion (CRISPR Future Research)

a) Next-Generation CRISPR Advancements (Base and Prime Editing)

As CRISPR technology evolves, next-generation genome-editing tools such as base editing and prime editing have emerged as revolutionary advancements. These methods offer greater precision, reduced off-target effects, and expanded capabilities for treating genetic disorders. Base editing, first developed in 2016, allows the direct conversion of one DNA base pair into another without inducing double-strand breaks. It is highly effective for correcting point mutations that cause genetic diseases (Ali et al., 2024). In contrast, prime editing, introduced in 2019, enables more versatile genome modifications by incorporating new genetic sequences with minimal risk of unintended mutations (Gaudelli et al., 2017).

Base editing utilises deaminase enzymes fused with a catalytically inactive Cas9 (dCas9) or a nickase Cas9 (nCas9) to convert specific DNA bases, such as C→T or A→G, without requiring DNA strand cleavage (Anzalone et al., 2019). This technology has demonstrated significant potential for treating monogenic disorders, including sickle cell anemia and Duchenne muscular dystrophy, by precisely correcting pathogenic mutations (Kim et al., 2020). Despite its accuracy, base editing is limited to specific types of single-nucleotide changes and requires further optimisation to expand its editing scope.

Prime editing, described as a "search-and-replace" genome editing technique, employs a reverse transcriptase enzyme coupled with Cas9 to insert new genetic sequences at targeted locations (Ali et al., 2024). Unlike conventional CRISPR-Cas9, which relies on homology-directed repair (HDR), prime editing does not introduce double-strand breaks, reducing the risk of large deletions or chromosomal rearrangements. This method has successfully corrected disease-causing mutations

*Corresponding Author: **Sehar Rafique**

in cellular models of cystic fibrosis and Tay-Sachs disease, demonstrating its therapeutic promise (Anzalone et al., 2019).

Developing these next-generation CRISPR technologies marks a significant step toward safer and more efficient gene therapies. However, challenges such as delivery efficiency, potential off-target effects, and immune responses must be addressed before clinical applications can be widely implemented (Ali et al., 2024). Future research will focus on improving editing precision, expanding target accessibility, and developing optimised delivery methods for therapeutic use.



Figure 6: CRISPR DNA Base-Editing Tools. (A) DNA Base-editing. DNA base-editors have two key components: a Cas enzyme for programmable DNA binding and a single-stranded DNA modifying enzyme for targeted nucleotide alteration. Two classes of DNA base-editors have been identified: cytosine base-editors and adenine base-editors. Cytosine deamination produces uracil, which base pairs with thymidine in DNA. The fusion of uracil DNA glycosylase inhibitor (UGI) inhibits the activity of uracil N-glycosylate (UNG), thereby increasing the editing efficiency of cytosine base-editing in human cells. Adenosine deamination produces inosine, which shares the same base pairing preferences as guanosine in DNA. Collectively, cytosine and adenine base-editing can install all four transition mutations (C→T, T→C, A→G, and G→A). (B) Prime-editing. Prime-editors utilise an engineered reverse transcriptase fused to Cas9 nickase and a prime-editing guide RNA (pegRNA). The pegRNA contains the sequence complementary to the target sites that directs nCas9 to its target sequence, along with an additional sequence specifying the desired sequence changes. Prime-editors expand the scope of DNA editing to include all transition and transversion mutations and small insertion and deletion mutations (Kantor et al., 2020).

b) CRISPR and AI Integration for Precision Editing

Integrating artificial intelligence (AI) with CRISPR technology can revolutionise precision genome editing by enhancing guide RNA (gRNA) design, predicting off-target effects, and optimising gene-editing outcomes. AI-driven bioinformatics tools leverage machine learning algorithms to analyse vast genomic datasets, improving the efficiency and accuracy of CRISPR-based modifications (Ali et al., 2024). Using AI, researchers can develop more reliable and safer gene-editing approaches, minimising the risks associated with unintended mutations.

One key application of AI in CRISPR is the design of highly specific gRNAs. Traditional gRNA selection methods rely on empirical testing and trial-and-error approaches, which can be time-consuming and inefficient. AI-powered platforms such as DeepCRISPR and CRISPR-Net utilise neural networks to predict the best gRNA sequences with minimal off-target activity, significantly improving editing precision (Wang et al., 2019). These models consider chromatin accessibility, sequence context, and cellular environment, providing optimised gRNA designs for therapeutic applications.

AI also plays a crucial role in identifying potential off-target sites by analysing whole-genome sequences. Computational tools such as CRISPRoff and GUIDE-seq predict and validate off-target effects, allowing researchers to refine CRISPR systems before clinical use (Ali et al., 2024). This capability is significant for ensuring the safety of gene-editing therapies, as unintended genetic modifications could lead to unpredictable consequences, including cancer risk and immune system activation.

Beyond improving editing accuracy, AI is being integrated with CRISPR-based diagnostics for early disease detection. AI-powered CRISPR diagnostics have been developed for infectious diseases, including COVID-19, tuberculosis, and Zika virus, enabling rapid and highly sensitive detection of pathogenic DNA and RNA sequences (Armenta et al., 2022). By automating the analysis of CRISPR-based biosensors, AI enhances diagnostic efficiency and reduces human error, making these technologies more accessible for widespread use.

The combination of AI and CRISPR represents a significant advancement in biotechnology, offering unparalleled precision and efficiency in genome engineering. However, ethical concerns surrounding AI-driven genetic modifications must be addressed, including data privacy, algorithmic bias, and equitable access to AI-enhanced gene-editing technologies (Ali et al., 2024). Ongoing research aims to develop transparent and ethical AI frameworks that ensure responsible implementation of CRISPR-based innovations.

c) Final Thoughts on Ethical, Medical, and Agricultural Advancements

The rapid advancement of CRISPR technology has ushered in a new era of possibilities across medicine, agriculture, and ethical considerations. In medicine, CRISPR-based therapies are poised to transform the treatment of genetic disorders, cancers, and infectious diseases by providing targeted and long-lasting interventions (Ali et al., 2024). Clinical trials are underway for CRISPR therapies to cure sickle cell disease and beta-thalassemia, with promising early results demonstrating the potential for permanent genetic corrections (Frangoul et

*Corresponding Author: **Sehar Rafique**

al., 2021). However, regulatory approval and long-term safety assessments remain crucial for ensuring the responsible use of CRISPR in clinical settings.

CRISPR has revolutionised crop improvement in agriculture by enabling precise genetic modifications to enhance yield, pest resistance, and climate adaptability. Gene-edited crops such as CRISPR-modified wheat and rice have been developed to improve nutritional content and disease resistance while reducing reliance on chemical pesticides (Kwon et al., 2022). Unlike traditional genetically modified organisms (GMOs), CRISPR-edited plants do not involve the insertion of foreign DNA, making them more acceptable to regulatory bodies and consumers. Nevertheless, public perception and policy frameworks continue to influence the adoption of CRISPR in agriculture, necessitating transparent communication and regulatory alignment across different countries.

Ethical considerations surrounding CRISPR remain a subject of intense debate, particularly in the context of human germline editing. While CRISPR offers the potential to eradicate hereditary diseases, concerns about "designer babies" and unintended genetic consequences have led to calls for strict regulatory oversight (Ali et al., 2024). The case of He Jiankui, who controversially edited the genomes of twin embryos to confer HIV resistance, highlighted the urgent need for global ethical guidelines and responsible research practices (Hirsch et al., 2019). Ethical frameworks must be established to balance scientific progress with ethical responsibility, ensuring that CRISPR is used for beneficial and socially acceptable purposes.

In conclusion, CRISPR remains at the forefront of genetic innovation, with next-generation advancements in base and prime editing, AI integration, and clinical applications shaping the future of genome engineering. While the potential benefits of CRISPR in medicine, agriculture, and diagnostics are vast, safety, ethics, and regulation challenges must be carefully navigated. As research continues to expand the capabilities of CRISPR, it is imperative to foster interdisciplinary collaboration among scientists, policymakers, and ethicists to ensure the responsible and equitable use of genome-editing technologies. With continued advancements and ethical considerations, CRISPR has the potential to redefine the boundaries of genetic medicine and biotechnology, ultimately improving human health and environmental sustainability (Ali et al., 2024).

References

1. Ali, F., Hameed, A., Rehman, A., et al. (2024). CRISPR System Discovery, History, and Future Perspective. *John Wiley & Sons Ltd.* DOI: 10.1002/9781394209156.ch8
2. Aljabali, A. A. A., El-Tanani, M., & Tambuwala, M. M. (2024). *Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery*. *Journal of Drug Delivery Science and Technology*, *92*, 105338. https://doi.org/10.1016/j.jddst.2024.105338
3. Anzalone AV, Koblan LW, Liu DR (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38:824-844. doi: 10.1038/s41587-020-0561-9
4. Anzalone, A. V., Randolph, P. B., Davis, J. R., et al. (2019). Search-and-replace genome editing with prime editing. *Nature*, *576*(7785), 149-157.
5. Arora, L., & Narula, A. (2017). Gene Editing and Crop Improvement Using CRISPR-Cas9 System. *Frontiers in Plant Science*, *8*, 1932. https://doi.org/10.3389/fpls.2017.01932
6. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:1709-1712. doi: 10.1126/science.1138140
7. Barrangou, R., & Doudna, J. A. (2016). *Applications of CRISPR technologies in research and beyond*. *Nature Biotechnology*, *34*(9), 933–941. https://doi.org/10.1038/nbt.3659
8. Barrangou, R., & Horvath, P. (2017). *A decade of discovery: CRISPR functions and applications*. *Nature Microbiology*, *2*(7), 17092. https://doi.org/10.1038/nmicrobiol.2017.92
9. Bhardwaj, S., Kesari, K. K., Rachamalla, M., Mani, S., Ashraf, G. M., Jha, S. K., Kumar, P., Ambasta, R. K., Dureja, H., Devkota, H. P., Gupta, G., Chellappan, D. K., Singh, S. K., Dua, K., Ruokolainen, J., Kamal, M. A., Ojha, S., & Jha, N. K. (2022). **CRISPR-Cas9 applications in neurology: Gene editing for Alzheimer's and Parkinson's disease**. *Journal of Advanced Research*, *40*, 207-221.
10. Bhattacharjee, R., Jana, A., Nandi, A., Sinha, A., Bhattacharjee, A., Mitra, S., Kar, S., Dey, A., Singh, S. K., Varma, R. S., & Ghosh, S. (2022). *Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical applications*. *Materials & Design*, *224*, 111415. https://doi.org/10.1016/j.matdes.2022.111415
11. Bolukbasi, M. F., Gupta, A., & Wolfe, S. A. (2015). *Creating and evaluating accurate CRISPR-Cas9 targets in the human genome*. *Nature Biotechnology*, *33*(2), 136–142. https://doi.org/10.1038/nbt.3117
12. Bothmer, A., Phadke, T., Barrera, L. A., Margulies, C. M., Lee, C. S., & Stoddard, T. J. (2017). *Characterisation of the interplay between DNA repair pathways in CRISPR-mediated genome editing*. *Nature Communications*, *8*, 1245. https://doi.org/10.1038/s41467-017-01468-8
13. Brokowski, C. (2018). Do CRISPR Germline Ethics Statements Cut It? *CRISPR Journal*, *1*, 115–125.
14. Carlson, D. F., Tan, W., Lillico, S. G., et al. (2016). Efficient TALEN-mediated gene knockout in livestock. *Proceedings of the National Academy of Sciences*, *109*(43), 17382-17387.

*Corresponding Author: **Sehar Rafique**

15. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., et al. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. *Molecular Cancer, 23*(9), 1-45. https://doi.org/10.1186/s12943-023-01925-5
16. Chen, S., Sanjana, N. E., Zheng, K., et al. (2019). Genome-wide CRISPR screen identifies key regulators of Parkinson's disease-related alpha-synuclein toxicity. *Nature Genetics, 51*(4), 654-664.
17. Choi, K. R., Jang, W. J., Yang, D., Cho, J. S., Park, D., & Lee, S. Y. (2021). *CRISPR genome engineering for microbial synthetic biology*. *Nature Reviews Microbiology, 19*(6), 303–318. https://doi.org/10.1038/s41579-020-00467-3
18. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). *Multiplex genome engineering using CRISPR/Cas systems*. *Science, 339*(6121), 819–823. https://doi.org/10.1126/science.1231143
19. Crispo, M., Mulet, A. P., Tesson, L., Barrera, N., Cuadro, F., dos Santos-Neto, P. C., Nguyen, T. H., & Anegón, I. (2015). *Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes*. *PLoS ONE, 10*(8), e0136690. https://doi.org/10.1371/journal.pone.0136690
20. Dominguez, A. A., Lim, W. A., & Qi, L. S. (2022). *Beyond editing: Repurposing CRISPR-Cas9 for precision genome regulation and epigenome engineering*. *Nature Reviews Molecular Cell Biology, 23*(1), 8–23. https://doi.org/10.1038/s41580-021-00425-1
21. Doudna JA, Charpentier E (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346:1258096. doi: 10.1126/science.1258096
22. Doudna, J. A. (2020). *The promise and challenge of therapeutic genome editing*. *Nature, 578*(7794), 229–236. https://doi.org/10.1038/s41586-020-1978-5
23. Doudna, J. A., & Charpentier, E. (2012). *The new frontier of genome engineering with CRISPR-Cas9*. *Science, 346*(6213), 1258096. https://doi.org/10.1126/science.1258096
24. Eckerstorfer, M. F., Engelhard, M., Heissenberger, A., et al. (2019). Plants developed by new genetic modification techniques—Comparison of existing regulatory approaches in the EU and non-EU countries. *Frontiers in Bioengineering and Biotechnology, 7*, 26.
25. Eyquem, J., et al. (2017). *Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection*. Nature, 543, 113-117.
26. Frangoul, H., et al. (2021). *CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia*. New England Journal of Medicine, 384, 252-260.
27. Gao, C. (2020). *The future of CRISPR technologies in agriculture*. *Nature Reviews Molecular Cell Biology, 21*(11), 681–682. https://doi.org/10.1038/s41580-020-00288-7
28. Gao, Y., Wu, H., Wang, Y., et al. (2017). Single Cas9 nickase induced generation of NRAMP1 knockin cattle with reduced off-target effects. *Genome Biology, 18*(1), 13.
29. Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012). *Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria*. *Proceedings of the National Academy of Sciences, 109*(39), E2579–E2586. https://doi.org/10.1073/pnas.1208507109
30. Gaudelli, N. M., Komor, A. C., Rees, H. A., et al. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature, 551*(7681), 464-471.
31. Gibson, D. G., Glass, J. I., Lartigue, C., et al. (2010). Creation of a bacterial cell controlled by a chemically synthesised genome. *Science, 329*(5987), 52-56.
32. Glass, Z., Lee, M., Li, Y., & Xu, Q. (2018). *Engineering lipid-based nanoparticles for CRISPR delivery*. *Science Advances, 4*(10), eaav6190. https://doi.org/10.1126/sciadv.aav6190
33. Gonzalez-Avila, L. U., Vega-López, J. M., Pelcastre-Rodríguez, L. I., et al. (2021). The Challenge of CRISPR-Cas Toward Bioethics. *Frontiers in Microbiology, 12*, 657981. https://doi.org/10.3389/fmicb.2021.657981
34. Greely, H. T. (2019). Human Germline Genome Editing: An Assessment. *CRISPR Journal, 2*, 253–265.
35. Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). *Off-target effects in CRISPR/Cas9 gene editing*. *Frontiers in Bioengineering and Biotechnology, 11*, 1143157. https://doi.org/10.3389/fbioe.2023.1143157
36. He, D., et al. (2021). *CRISPR-edited NK cells for cancer therapy*. Molecular Therapy, 29, 1234-1246.
37. Hirsch, T., Lee, T., and Zhang, S. (2019). Ethical implications of CRISPR and human germline editing. *Bioethics Review, 37*(4), 203-219.
38. Hsu, P. D., Lander, E. S., & Zhang, F. (2014). *Development and applications of CRISPR-Cas9 for genome engineering*. *Cell, 157*(6), 1262–1278. https://doi.org/10.1016/j.cell.2014.05.010
39. Hu, W., Kaminski, R., Yang, F., et al. (2014). RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. *Proceedings of the National Academy of Sciences, 111*(31), 11461-11466.
40. Ishii, T. (2017). *Germline genome-editing research and its socioethical implications*. *Trends in Molecular Medicine, 23*(6), 479–487. https://doi.org/10.1016/j.molmed.2017.04.005

*Corresponding Author: **Sehar Rafique**

41. Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). *The nucleotide sequence of the iap gene is responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product*. *Journal of Bacteriology, 169*(12), 5429–5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987
42. Jabbar, A., Zulfiqar, F., Mahnoor, M., et al. (2021). Advances and Perspectives in the Application of CRISPR-Cas9 in Livestock. *Molecular Biotechnology*. https://doi.org/10.1007/s12033-021-00347-2
43. Jeong, S. H., Lee, H. J., & Lee, S. J. (2023). Recent Advances in CRISPR-Cas Technologies for Synthetic Biology. *Journal of Microbiology, 61*(1), 13–36. https://doi.org/10.1007/s12275-022-00005-5
44. Jiang, W., Yang, H., & Liu, Y. (2021). CRISPR-based metabolic engineering for biofuel production. *Current Opinion in Biotechnology, 67*, 1-8.
45. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). *A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity*. *Science, 337*(6096), 816–821. https://doi.org/10.1126/science.1225829
46. Jolany Vangah, S., Katalani, C., Boone, H. A., Hajizade, A., Sijercic, A., & Ahmadian, G. (2020). CRISPR-Based Diagnosis of Infectious and Noninfectious Diseases. *Biological Procedures Online*
47. Kantor, A., McClements, M. E., & MacLaren, R. E. (2020). CRISPR-Cas9 DNA base-editing and prime-editing. *International Journal of Molecular Sciences, 21*(17), 6240
48. Kellner, M. J., Koob, J. G., Gootenberg, J. S., et al. (2019). SHERLOCK: Nucleic acid detection with CRISPR nucleases. *Nature Protocols, 14*(10), 2986-3012.
49. Kennedy, E. M., Cullen, B. R. (2014). Bacterial CRISPR/Cas DNA endonucleases: A new tool to combat human viruses. *Genes & Development, 29*(5), 461-470.
50. Kleinstiver, B. P., et al. (2016). High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature, 529*(7587), 490-495.
51. Knott GJ, Doudna JA (2018). CRISPR-Cas guides the future of genetic engineering. Science 361:866-869. doi: 10.1126/science.aat5011
52. Komor, A. C., Badran, A. H., & Liu, D. R. (2017). *CRISPR-based technologies for the manipulation of eukaryotic genomes*. *Cell, 168*(1–2), 20–36. https://doi.org/10.1016/j.cell.2016.10.044
53. Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). *Do not edit the human germ line*. *Nature, 519*(7544), 410–411. https://doi.org/10.1038/519410a
54. Ledford, H. (2019). *CRISPR conundrum: Strict gene-editing rules put Europe at odds with global drive for innovation*. *Nature, 570*(7760), 16–18. https://doi.org/10.1038/d41586-019-01770-x
55. Li, H., Au, N. P. B., Zhang, W. Y., et al. (2021). Non-viral strategies for delivering CRISPR gene-editing tools. *Advances in Drug Delivery Reviews, 168*, 101-117.
56. Li, H., Sheng, C., Liu, Y., et al. (2018). Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. *Nature Communications, 9*(1), 482.
57. Li, M., Li, X., Zhou, Z., et al. (2016). Reassess the four yield-related genes Gn1a, DEP1, GS3, and IPA1 in rice using a CRISPR/Cas9 system—Frontiers *in Plant Science, 7*, 377.
58. Liao, J. C., Mi, L., Pontrelli, S., & Luo, S. (2016). Fuelling the future: Microbial engineering for sustainable biofuel production. *Nature Reviews Microbiology, 14*(5), 288-304.
59. Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014). *Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery*. *eLife, 3*, e04766. https://doi.org/10.7554/eLife.04766
60. Liu, X., et al. (2022). *PD-1–deficient CAR-T cells in solid tumors*. Cell, 185, 239-253.
61. Lu, Y., et al. (2020). *CRISPR-Edited PD-1–Deficient T Cells in Patients with Advanced Cancer*. New England Journal of Medicine, 382, 1803-1814.
62. Lyall, J., Irvine, R. M., Sherman, A., et al. (2011). Suppressing influenza virus replication in chickens through RNA interference. *Science, 331*(6014), 223-226.
63. Mali P, Esvelt KM, Church GM (2013). Cas9 as a versatile tool for engineering biology. Nat. Methods 10:957-963. Doi: 10.1038/nmeth.264
64. Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015). *Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibiting nonhomologous end joining*. *Nature Biotechnology, 33*(5), 538–542. https://doi.org/10.1038/nbt.3190
65. Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., & Siegwart, D. J. (2017). *Non-viral CRISPR delivery: The path to translation into therapeutics*. *Accounts of Chemical Research, 50*(3), 619–627. https://doi.org/10.1021/acs.accounts.6b00523
66. Miller, S. M., Wang, H., Oakes, B. L., et al. (2020). Delivery strategies for genome editing in neurodegenerative diseases. *Current Opinion in Biotechnology, 61*, 88-96.
67. Mojica, F. J. M., & Díez-Villaseñor, C. (2013). *Discovery and seminal developments in the CRISPR field*. *Philosophical Transactions of the Royal Society B, 368*(1612), 20120358. https://doi.org/10.1098/rstb.2012.0358

*Corresponding Author: **Sehar Rafique**

68. NASEM. (2017). Human Genome Editing: Science, Ethics, and Governance. National Academies Press.
69. NASEM. (2017). Human Genome Editing: Science, Ethics, and Governance. National Academies Press
70. Nekrasov, V., Wang, C., Win, J., Lanz, C., Weigel, D., & Kamoun, S. (2017). *Rapid generation of a transgene-free powdery mildew resistant tomato by genome deletion*. *Scientific Reports, 7*, 482. https://doi.org/10.1038/s41598-017-00578-x
71. Nielsen, J., & Keasling, J. D. (2016). Engineering cellular metabolism. *Cell, 164*(6), 1185-1197.
72. Pinder, J., Salsman, J., & Dellaire, G. (2015). *Nuclear domain "hubs" and their role in genome stability and repair*. *Nucleus, 6*(2), 107–123. https://doi.org/10.1080/19491034.2015.1025191
73. Proudfoot, C., Carlson, D. F., Huddart, R., et al. (2015). Genome edited sheep and cattle. *Transgenic Research, 24*(1), 147-153.
74. Ran, F. A., Hsu, P. D., Lin, C. Y., Gootenberg, J. S., Trevino, A. E., Scott, D. A., & Zhang, F. (2013). *Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity*. *Cell, 154*(6), 1380–1389. https://doi.org/10.1016/j.cell.2013.08.021
75. Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., & Taheri, M. (2022). Strategies to overcome the main challenges of using CRISPR-Cas9 to replace cancer therapy. *Molecular Cancer, 21*(1)
76. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016). *Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA*. *Nature Biotechnology, 34*(3), 339–344. https://doi.org/10.1038/nbt.3481
77. Ro, D. K., Paradise, E. M., Ouellet, M., et al. (2006). Production of the antimalarial drug precursor artemisinic acid in engineered yeast. *Nature, 440*(7086), 940-943.
78. Sen, T., & Thummer, R. P. (2022). CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics. *Neurotoxicity Research, 40*, 1597-1623. https://doi.org/10.1007/s12640-022-00564-w
79. Shew, A. M., Nalley, L. L., Snell, H. A., et al. (2018). CRISPR versus GMOs: Public acceptance and valuation. *Global Food Security, 19*, 71–80.
80. Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016). *Rationally engineered Cas9 nucleases with improved specificity*. *Science, 351*(6268), 84–88. https://doi.org/10.1126/science.aad5227
81. Soldner, F., Laganière, J., Cheng, A. W., et al. (2016). Isogenic pluripotent stem cell generation differs exclusively at two early onset Parkinson's disease-associated SNPs. *Cell, 146*(1), 11-22.
82. Stadtmauer, E.A., et al. (2020). *CRISPR-engineered T cells in patients with refractory cancer*. Science, 367(6481), eaba7365.
83. Stefanoudakis, D., et al. (2023). *The Potential Revolution of Cancer Treatment with CRISPR Technology*. Cancers, 15, 1813. https://doi.org/10.3390/cancers15061813
84. Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). *DNA interrogation by the CRISPR RNA-guided endonuclease Cas9*. *Nature, 507*(7490), 62–67. https://doi.org/10.1038/nature13011
85. Strich, J. R., & Chertow, D. S. (2019). CRISPR-Cas biology and its application to infectious diseases. *Journal of Clinical Microbiology, 57*(4), e01307-18. https://doi.org/10.1128/JCM.01307-18
86. Tan, W., Proudfoot, C., Lillico, S. G., & Whitelaw, C. B. A. (2022). *Gene-editing livestock: A step closer to sustainable agriculture*. *Genome Biology, 23*(1), 61. https://doi.org/10.1186/s13059-022-02669-8
87. Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., & Behlke, M. A. (2018). *A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex improves the specificity of CRISPR genome editing in human cells*. *Molecular Therapy, 26*(2), 279–287. https://doi.org/10.1016/j.ymthe.2017.11.012
88. Van Eenennaam, A. L. (2019). Application of genome editing in farm animals: Cattle. *Transgenic Research, 28*(1), 93-100.
89. Wang, H., Fu, Y., Dai, C., et al. (2018). CRISPR-Cas9 targeting of *BACE1* alleviates Alzheimer's disease pathology in vivo. *Molecular Therapy, 26*(7), 1780-1792.
90. Wang, Y., Cheng, X., Shan, Q., et al. (2014). Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew. *Nature Biotechnology, 32*(9), 947–951.
91. Weber W, Fussenegger M (2020). Emerging biomedical applications of synthetic biology. Nat. Rev. Genet. 21:178-191. doi: 10.1038/s41576-019-0175-7
92. Whitworth, K. M., Rowland, R. R., Ewen, C. L., et al. (2015). Gene-edited pigs are protected from porcine reproductive and respiratory syndrome virus. *Nature Biotechnology, 34*(1), 20-22.
93. Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016). *Biology and applications of CRISPR systems: Harnessing nature's toolbox for genome engineering*. *Cell, 164*(1–2), 29–44. https://doi.org/10.1016/j.cell.2015.12.035
94. Xu, L., Yang, H., Gao, Y., et al. (2019). CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. *New England Journal of Medicine, 381*(13), 1240-1247.

*Corresponding Author: **Sehar Rafique**

95. Yin, C., Zhang, T., Qu, X., et al. (2017). In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models. *Molecular Therapy*, *25*(5), 1168-1186.
96. Zhang M-L, Li H-B, Jin Y (2024). Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy. Front. Genet. 15:1364742. doi: 10.3389/fgene.2024.1364742
97. Zhang, Y., & Showalter, A. M. (2022). *CRISPR/Cas9 genome editing technology: A valuable tool for understanding plant cell wall biosynthesis and function*. *Frontiers in Plant Science*, *13*, 589517. https://doi.org/10.3389/fpls.2020.589517
98. Zhou, C., Xue, M., Qin, T., et al. (2020). Suppression of *BACE1* gene expression in Alzheimer's disease using CRISPR interference. *Neurobiology of Aging*, *93*, 70-79.

*Corresponding Author: **Sehar Rafique**